Name	Current Price - Today's Change	Market Cap
JOHNSON & JOHNSON (JNJ)	$62.76 - $0.39(0.63%)	172.83 B
PFIZER INC (PFE)	$17.88 - $0.04(0.22%)	144.93 B
NOVARTIS AG ADS (NVS)	$53.58 - $0.50(0.94%)	120.96 B
MERCK & COMPANY; INC. (MRK)	$36.47 - $0.12(0.33%)	113.83 B
GLAXOSMITHKLINE PLC (GSK)	$38.47 - $0.35(0.92%)	107.74 B
SANOFI-AVENTIS ADS (SNY)	$36.29 - $0.38(1.06%)	93.43 B
ABBOTT LABORATORIES (ABT)	$53.35 - $0.00(0.00%)	83.48 B
ASTRAZENECA PLC (AZN)	$44.11 - $0.98(2.27%)	62.34 B
AMGEN INC (AMGN)	$57.21 - $0.25(0.44%)	58.38 B
TEVA PHARMACEUTICAL LTD (TEVA)	$57.10 - $0.18(0.32%)	51.77 B

STOCK ANALYSIS

Pfizer Feeling Frisky (PFE, LLY, FRX, GSK)
Investors are worried about Lipitor's patent running out, but Pfizer has many other ways to give your portfolio a r...

Fairholme's Favorite Stocks (PFE, WLP, UNH, BRK-B, BNI)
When picking undervalued stocks with excellent long-term fundamentals, few are better than Bruce Berkowitz and Fai...

Several Giants Set To Report (CSCO, BRCM, PFE, V)
These big companies have yet to report earnings - and it will be worth it to hear.

Let's Play The Dow Dividend Game (GIS, TOT, NZT, CVX, KFT)
These three companies are strong alternatives to Dow dividend payers.

There's Nothing Generic About the Profits (TEVA, WPI)
Any healthcare reform will include severe cost cutting. Giving your portfolio a dose of generic-dug makers will hel...

View All Stock Analysis

PFE RELATED HEADLINES

FDA Agreements Should Be Public
One of the biggest initiatives Margaret Hamburg has announced since she became head of the Food and Drug Administration is a new push to make FDA's doings more transparent to the outside world. Yesterday's bad news for Seattle-based Cell Therapeutics represents one way in which the regulator fails to make sure investors have information they ...
Forbes.com 2/9/2010

A Win For Crestor, AstraZeneca
The Food and Drug Administration is approving the statin drug Crestor to prevent heart attacks, strokes, and heart procedures in patients with normal levels of bad cholesterol but high levels of c-reactive protein, a marker for heart inflammation, according to a Q&A on the FDA Web site. The new approval could result in millions more ...
Forbes.com 2/8/2010

Pfizer (PFE) Trading Just Under Resistance Level With Bearish Technicals
Pfizer (NYSE: PFE) ended the last trading session at $17.96. So far the stock has hit a 52-week low of $11.62 and 52-week high of $20.36. Pfizer stock has been showing support around 17.33 and resistance in the 18.49 range. Technical indicators for the stock are Bearish and S&P gives PFE a positive 4 STAR (out of 5) buy rating. PFE appears on the Investors Observer Hedged Dividend Income list. For a hedged play on this stock, look at a Jun '10 18 covered call for a net debit in the $16.75 area. That is also the break even stock price for this trade. This covered call has a 131 day duration, provides 6.74%...
At Market Intelligence Center 2/8/2010

The Profit Principle
Nicholas Kaiser got into Islamic investing by accident, but there's nothing haphazard about his Amana funds.
Forbes.com 2/8/2010

Two Pharmas
Featuring Wallace Forbes and Damien Conover.
Forbes.com 2/4/2010

Where's The Sunshine For Unemployables?
A rise in structural unemployment, coupled with the urge to pay down debt, is not encouraging, but I'm still inclined to be bullish.
Forbes.com 2/4/2010

View All Headlines